Physician profile
Jose C Suarez
NPI 1346238474
$5,128.79
in general payments reported to CMS, 2019-2025
31 companies · $1,580 in 2025
The $1,580 reported for 2025 was more than what a typical Hematology & Oncology provider received nationally (typical 2025 total: $686).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $224 · 2020: $19.90 · 2021: $31.97 · 2022: $662 · 2023: $1,371 · 2024: $1,240 · 2025: $1,580.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,163 · Education: $28.14.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,162.60 |
| Education | $28.14 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $889.76 | 2020-2025 | Enhertu, Imfinzi |
| Merck Sharp & Dohme LLC | $627.14 | 2019-2025 | Keytruda, Lynparza, Keytruda Qlex |
| Daiichi Sankyo INC. | $578.19 | 2023-2025 | Enhertu, Injectafer |
| E.R. Squibb & Sons, L.L.C. | $493.96 | 2021-2025 | Opdivo |
| Janssen Biotech, INC. | $382.76 | 2022-2025 | Carvykti, Rybrevant, Erleada |
| Regeneron Healthcare Solutions, INC. | $290.40 | 2022-2023 | Libtayo |
| Lilly USA, LLC | $245.60 | 2023-2025 | Verzenio, Jaypirca, Retevmo |
| Pfizer INC. | $245.25 | 2024-2025 | |
| Seagen INC. | $170.70 | 2022-2023 | Tukysa, Padcev |
| Emd Serono, INC. | $143.80 | 2022-2023 | Bavencio |
| Caris Mpi, INC. | $143.39 | 2025 | Mi Cancer Seek |
| Novartis Pharmaceuticals Corporation | $126.46 | 2024-2025 | |
| Cti Biopharma Corp. | $113.37 | 2023 | Vonjo |
| Bayer Healthcare Pharmaceuticals INC. | $94.92 | 2023-2025 | |
| Array Biopharma INC | $71.63 | 2023-2025 | Lorbrena, Braftovi, Mektovi |
Show all 31 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Jazz Pharmaceuticals INC. | $63.55 | 2025 | |
| Amgen INC. | $47.36 | 2022-2025 | Vectibix |
| Celgene Corporation | $46.21 | 2023 | |
| Eisai INC. | $46.04 | 2023-2024 | |
| Abbvie INC. | $34.17 | 2025 | |
| Beone Medicines USA, INC. | $32.54 | 2025 | Tevimbra |
| Sobi, INC | $32.15 | 2025 | |
| Takeda Pharmaceuticals U.S.A., INC. | $31.80 | 2025 | Alunbrig |
| Taiho Oncology, INC. | $29.79 | 2025 | |
| Tersera Therapeutics LLC | $27.98 | 2025 | Zoladex |
| Aimmune Therapeutics, INC. | $25.25 | 2025 | Vowst |
| Genentech USA, INC. | $24.11 | 2023 | Columvi, Polivy |
| Adc Therapeutics America, INC. | $23.63 | 2024 | |
| Myriad Genetic Laboratories, INC. | $18.40 | 2023 | Myrisk |
| Astellas Pharma US INC | $16.56 | 2023 | Padcev |
| Gilead Sciences, INC. | $11.92 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jose Suarez listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.